Latest Regulation News

Page 15 of 166
SkyCity Entertainment Group has secured the right to apply for two New Zealand online casino licences, committing NZ$30 million in licence fees before GST. The company still needs to complete the application process ahead of next year’s planned market opening.
Victor Sage
Victor Sage
13 Oct 2026
The US FDA has supported six of seven elements NeuroScientific Biopharmaceuticals put forward for its planned StemSmart Phase 2 Crohn’s disease trial. The remaining issue is a manufacturing control for viral contamination, while trial commencement remains targeted for the end of 2026 and subject to further requirements.
Ada Torres
Ada Torres
13 Oct 2026
Ionic Rare Earths has moved its Belfast magnet recycling project closer to construction while expanding into the United States through a proposed US$100 million joint venture. The progress comes with key funding, approvals and definitive agreements still outstanding.
Victor Sage
Victor Sage
13 Oct 2026
Nyrada has received supportive written feedback from the US FDA on its proposed pathway for taking Xolatryp into a US Phase IIa heart-attack trial. The regulator identified no major issues, but additional information and stability data are still required before the planned IND submission in the first half of 2027.
Ada Torres
Ada Torres
13 Oct 2026
WhiteHawk has completed its Quixxi acquisition after shareholders approved every resolution with more than 95% of non-associated votes. The deal adds AI governance, mobile application security and an international customer base, but execution now matters more than the strategic pitch.
Victor Sage
Victor Sage
12 Oct 2026
Echo IQ has secured an FDA supervisory review of the regulator’s Not Substantially Equivalent decision for EchoSolv HF. The review creates a formal route for reconsideration, but does not change the current regulatory determination or guarantee clearance.
Victor Sage
Victor Sage
12 Oct 2026
Stakk’s unaudited pro-forma revenue rose 16.5% to A$16.1 million in the first quarter of FY2027, implying an illustrative annualised pace above its full-year objective. The company has kept its A$55.2 million revenue and A$18.5 million EBITDA targets unchanged, stressing that one quarter does not establish the year.
Victor Sage
Victor Sage
12 Oct 2026
Acrux says the FDA has confirmed the evidence package required to take its female testosterone spray into Phase III trials for postmenopausal women with HSDD. The agency also indicated the company may apply for three years of data exclusivity if the product reaches submission.
Ada Torres
Ada Torres
12 Oct 2026
Zinc of Ireland has secured firm commitments for a $3.2 million placement to fund ARGO critical-mineral recovery work, VOLTA battery-recycling development and drilling at Kildare. The raise gives the company a defined execution schedule, but adds 180 million new shares before several commercial milestones remain unproven.
Victor Sage
Victor Sage
8 Oct 2026
Imricor has completed FDA review of the largest module in its US Premarket Approval application, with no deficiencies found in its ablation catheter or irrigation tubing. One operating-system issue remains for the RF-5000 System, but the company says it has already updated the software and is preparing its response.
Victor Sage
Victor Sage
8 Oct 2026
The Calmer Co has secured an initial Coles order for its Fiji Kava FZZR Piña Colada 10-pack, with rollout expected across 583 stores from the week commencing 12 October. The launch comes as sales and supermarket distribution of the company’s existing kava range continue to expand.
Victor Sage
Victor Sage
8 Oct 2026
InFocus is extending its Codexa platform from US sweepstakes gaming into licensed real-money online gambling markets, initially targeting Curaçao and crypto-native operators. Commercial availability is expected in early 2027, but the expansion still depends on product testing, regulatory registration and customer uptake.
Sophie Babbage
Sophie Babbage
8 Oct 2026

Browse the archive

Full archive